Join IASLC in helping to raise awareness about lung cancer during November’s Lung Cancer Awareness Month.
The International Association for the Study of Lung Cancer (IASLC) is leading a joint effort among a consortium of non-profit lung cancer patient advocacy organizations and individuals. This effort is designed to produce a coordinated, harmonized public awareness campaign for Lung Cancer Awareness Month (LCAM) in November 2016. A critical part of this campaign is to share and widely promote the stories of lung cancer survivors, caregivers and families of those who have been diagnosed with lung cancer. These stories will be displayed on the campaign’s brand new website www.lcam.org. They will also be shared on Twitter and Facebook feeds that have been set up specifically for the campaign. IASLC’s hope is that this effort will be maintained and expanded upon in subsequent years.
Summary:
Lung cancer accounts for about 27 percent of all cancer deaths and is by far the leading cause of cancer death among both men and women. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined.
It is important that IASLC members help communicate the vast threat lung cancer poses around the world. We need the public and the media to understand that new research, diagnosis and treatment breakthroughs in the last 10 years have brought new hope to patients and their families. To help spread the message about lung cancer, the IASLC created a series of fact sheets focusing on different regions around the globe and we translated them into several different languages. See our fact sheets.
IASLC encourages members to engage with local media and advocacy groups to bring more attention to the magnitude of this devastating disease. When you talk about lung cancer on social media, make sure you use #LCAM to consolidate all of our efforts during November. For more information on how you can become more active in helping bring attention to lung cancer, contact Becky Bunn, IASLC Projects Specialist, or visit our advocacy page.
